INT300261

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.22
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 5.82
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (ABCB6) mitochondrion (ABCB6) Golgi apparatus (ABCB6)
ATPase activity (ABCB6) plasma membrane (ABCB6) transmembrane transport (ABCB6)
ABCB6 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 2 59.60 Quite High
fluoxetine 1 51.72 Quite High
abdominal pain 7 34.88 Quite Low
methadone 35 5.00 Very Low Very Low Very Low
alcohol 28 5.00 Very Low Very Low Very Low
Bioavailability 14 5.00 Very Low Very Low Very Low
Inflammation 7 5.00 Very Low Very Low Very Low
palliative 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Thrombosis 7 99.42 Very High Very High Very High
Fever 29 99.20 Very High Very High Very High
Hypersensitivity 115 98.88 Very High Very High Very High
Disease 50 98.86 Very High Very High Very High
Anaphylaxis 7 97.94 Very High Very High Very High
Cancer 20 93.60 High High
Adenocarcinoma 4 91.76 High High
Thrombocytopenia 7 85.16 High High
Lymphopenia 7 84.32 Quite High
Leukopenia 7 83.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Among 112 patients with ABC HSR who were rechallenged, an anaphylactic or immediate type of hypersensitivity reaction occurred in 20%.15 Therefore, patients with clinically suspected ABC HSR should not be rechallenged.
Positive_regulation (suspected) of ABC associated with anaphylaxis and hypersensitivity
1) Confidence 0.22 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2835563 Disease Relevance 0.80 Pain Relevance 0
In an analysis of 5,332 patients enrolled in ABC clinical trials, being ART-experienced at the start of ABC therapy and being of African descent were associated with a nearly 40% reduction in the risk of hypersensitivity.19 Patients of white race were found to be at significantly greater risk in another study of a population with a low percentage of ethnic minorities.14 Accumulated data suggest that factors that predict a lower likelihood to develop ABC HSR are: male sex, African racial origin, more advanced disease, and being an antiretroviral-experienced patient before initiation of ABC.12,14
Positive_regulation (develop) of ABC associated with hypersensitivity and disease
2) Confidence 0.22 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2835563 Disease Relevance 0.45 Pain Relevance 0
Disseminated intravascular coagulation has also been reported as a manifestation of ABC HSR.20
Positive_regulation (manifestation) of ABC associated with thrombosis
3) Confidence 0.19 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2835563 Disease Relevance 1.30 Pain Relevance 0
There have been case reports of patients who developed the ABC HSR after re-initiation of ABC after a hiatus in taking the medication, but this occurrence is believed to be rare.16 Interestingly, these patients had no symptoms of HSR during the first period of ABC administration.
Positive_regulation (initiation) of ABC
4) Confidence 0.19 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2835563 Disease Relevance 0.89 Pain Relevance 0
In an analysis of 5,332 patients enrolled in ABC clinical trials, being ART-experienced at the start of ABC therapy and being of African descent were associated with a nearly 40% reduction in the risk of hypersensitivity.19 Patients of white race were found to be at significantly greater risk in another study of a population with a low percentage of ethnic minorities.14 Accumulated data suggest that factors that predict a lower likelihood to develop ABC HSR are: male sex, African racial origin, more advanced disease, and being an antiretroviral-experienced patient before initiation of ABC.12,14
Positive_regulation (initiation) of ABC associated with hypersensitivity and disease
5) Confidence 0.19 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2835563 Disease Relevance 0.46 Pain Relevance 0
A study of 145 patients who interrupted ABC treatment showed 1 case of hypersensitivity but no statistical difference in incidence between the study patients who did not interrupt ABC.17
Positive_regulation (interrupted) of ABC associated with hypersensitivity
6) Confidence 0.19 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2835563 Disease Relevance 0.91 Pain Relevance 0
In an analysis of 5,332 patients enrolled in ABC clinical trials, being ART-experienced at the start of ABC therapy and being of African descent were associated with a nearly 40% reduction in the risk of hypersensitivity.19 Patients of white race were found to be at significantly greater risk in another study of a population with a low percentage of ethnic minorities.14 Accumulated data suggest that factors that predict a lower likelihood to develop ABC HSR are: male sex, African racial origin, more advanced disease, and being an antiretroviral-experienced patient before initiation of ABC.12,14
Positive_regulation (enrolled) of ABC associated with hypersensitivity and disease
7) Confidence 0.19 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2835563 Disease Relevance 0.42 Pain Relevance 0
structure model of CpABC was generated by Modeller, a homologymodeling
Positive_regulation (generated) of CpABC
8) Confidence 0.13 Published 2010 Journal Bioinformation Section Body Doc Link PMC2957761 Disease Relevance 0 Pain Relevance 0.05
Active EGFR signaling may lead to resistance by upregulation of ATP-binding cassette (ABC) proteins.
Positive_regulation (upregulation) of ABC
9) Confidence 0.09 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886327 Disease Relevance 0.59 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox